The global biopharmaceutical landscape is currently witnessing a massive infrastructure shift, characterized by record-breaking capital investments and a fundamental rethinking of how drugs move from the laboratory to the patient. At the heart of this transformation is FUJIFILM Biotechnologies, a Contract Development and Manufacturing Organization (CDMO) that is aggressively expanding its physical and digital footprint. Leading this charge is Maja Herold Pedersen, whose transition from Chief Quality Officer to Chief Operating Officer in September 2025 signals a strategic pivot: the company is moving beyond mere capacity building toward a new paradigm of operational autonomy powered by artificial intelligence.
The Physical Expansion: A $7 Billion Global Footprint
FUJIFILM Biotechnologies is currently orchestrating a multi-continental expansion project totaling approximately $7 billion. This capital deployment is not merely about increasing square footage; it is about establishing a standardized, interconnected global ecosystem capable of meeting the complex manufacturing demands of the next generation of biologics and advanced therapies.
Key Infrastructure Milestones:
- Holly Springs, North Carolina: The centerpiece of the U.S. strategy is a $3.2 billion commercial-scale cell culture manufacturing facility. The first phase successfully came online in September 2025, with a second phase of expansion slated for completion around 2028.
- Hillerød, Denmark: The European campus is undergoing a significant scaling effort, integrating eight new 20,000-liter bioreactors alongside two additional downstream processing streams to bolster capacity.
- Teesside, United Kingdom: In early 2026, the company unveiled the UK’s largest single-use CDMO facility, specifically designed for agile, high-throughput biomanufacturing.
- Madison, Wisconsin: Subsidiary FUJIFILM Cellular Dynamics invested $200 million into a new induced pluripotent stem cell (iPSC) manufacturing headquarters, which opened in May 2026, aiming to quadruple the company’s cell-production capabilities.
The Logic of Integration: The "kojoX" Model
To manage such a sprawling, heterogeneous network, the company has implemented "kojoX." The term, derived from the Japanese word kojo (meaning "improvement" and "factory") combined with an "X" for exponential scalability, represents a standardized bioproduction architecture. By enforcing uniformity in equipment, processes, and quality systems across all global sites, FUJIFILM aims to ensure that a validated drug-substance process can be transferred seamlessly to any equivalent line in the network. This standardization is designed to compress tech-transfer timelines and streamline the regulatory filing process, turning a complex, multi-site operation into a cohesive, modular engine.
Maja Herold Pedersen: The Architect of Operational Evolution
Maja Herold Pedersen’s rise to the COO role is a testament to the shifting requirements of modern pharmaceutical leadership. Her career, which began in quality and regulatory affairs, has given her a unique perspective on the intersection of compliance and innovation.
"I’ve never been a quality-function-only leader," Pedersen notes. "I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat; we need to make this work for patients in the end."
Her leadership philosophy is heavily influenced by her predecessor’s trust and her own inherent drive to push boundaries. Having navigated the rigid landscape of Good Manufacturing Practice (GMP) for years, she is uniquely positioned to bridge the gap between conservative regulatory requirements and the agile potential of modern technology.
Scaling AI: From "Genki" to Production
One of the most significant challenges in the highly regulated biopharma industry is the deployment of AI. Many companies remain trapped in the "pilot purgatory," where promising projects fail to scale due to validation and safety concerns. Pedersen, however, advocates for a more aggressive, controlled integration.
The "Genki" Ecosystem
Recognizing that employees would inevitably use public AI tools if denied official ones, Pedersen oversaw the development of "GenkiBot"—an internal, secure, large language model (LLM) environment. By keeping AI under the company’s security umbrella, FUJIFILM has been able to:
- Automate Deviation Management: The tool assists Subject Matter Experts (SMEs) in writing deviations, provides real-time coaching against established norms, and performs data-driven root cause analysis that moves beyond traditional, biased explanations.
- Increase Adoption: Currently used by roughly 50% of the relevant workforce for deviation tasks, the goal is near-universal adoption.
- Future-Proofing Tech Transfer: The next frontier for the Genki system is automating the tedious documentation and data-sequencing tasks associated with tech transfers, effectively "grabbing, organizing, and deploying" data to accelerate production timelines.
Maintaining Deterministic Guardrails
Pedersen’s approach to scaling AI is deceptively simple: she believes in "setting the tools free" to encourage innovation, while maintaining strict, deterministic guardrails for final GMP decisions.
"I don’t think everybody can make [GMP] decisions," Pedersen explains. "But the bigger the funnel we have of agents being coded, the better the quality of the selected variety of agents we’ll have at the end, which we can then take into a more controlled environment." This "playful" approach to development—treating AI agents like digital macros—empowers individuals to experiment, while the enterprise maintains the final word on regulatory compliance.
Cultural Transformation: The "9 People Fundamentals"
Technology alone is insufficient if the organizational culture remains hierarchical and risk-averse. To this end, FUJIFILM has implemented the "9 People Fundamentals," a framework designed to distribute decision-making power throughout the organization.
The core philosophy is to treat the company as a living organism: the "brain" provides direction and strategy, while the individual "cells"—the employees—are empowered to make decisions within their immediate spheres of influence.
Empowering the Workforce
- Decision-Making: By reducing unnecessary structure and governance, the company aims to release latent energy within the workforce.
- Accountability: Empowerment is not an invitation to chaos; it is a profound commitment to accountability. Leaders are currently undergoing a "Leaders for Life" cohort program, which focuses on self-awareness, emotional intelligence, and understanding one’s impact on the surrounding team.
- The Cost of Freedom: Pedersen is transparent about the difficulty of this culture. "Being empowered doesn’t come for free," she notes. "It holds you very accountable for what you’re doing and the moves you make."
Implications for the CDMO Industry
The path forward for FUJIFILM Biotechnologies has significant implications for the broader CDMO sector. By marrying massive physical infrastructure with a decentralized, AI-augmented operational model, the company is positioning itself to lead the industry in both volume and velocity.
Key Takeaways for the Future of Manufacturing:
- Regulatory-First AI: Success in this industry does not come from avoiding AI, but from integrating it into the compliance framework. Using AI to assist—rather than replace—human judgment in deviation management and documentation is the likely industry standard for the next decade.
- Standardization as a Competitive Advantage: The kojoX model demonstrates that in a global market, the ability to transfer technology between sites without friction is as valuable as the raw manufacturing capacity itself.
- The Shift Toward Distributed Leadership: As bioprocesses become more complex, the old, top-down decision-making models are becoming obsolete. Companies that successfully train their workforce to be autonomous, empowered, and tech-literate will likely outperform those that remain tethered to traditional, rigid hierarchies.
As FUJIFILM continues its global expansion, the integration of these digital and cultural initiatives will be the ultimate test of Pedersen’s leadership. If successful, the company will not just be a manufacturer of medicines, but a blueprint for the modern, agile, and intelligent pharmaceutical organization. Through the combination of "Genki" innovation and the "9 People Fundamentals," the company is setting a trajectory that moves beyond the simple scaling of facilities—it is scaling the very capacity of the organization to think, adapt, and deliver.
About the Author
